Sign up for ALS Link:

https://bit.ly/3CqGbhb

Thank you for joining the webinar!

We are admitting audience members from the waiting room

Please allow a few moments for the webinar to begin

HEALEY ALS Platform Trial

Community Q&A – December 18, 2025

Massachusetts General Hospital
Founding Member, Mass General Brigham

HARVARD MEDICAL SCHOOL

Healey & AMG Center
Sean M. Healey & AMG Center for ALS
at Massachusetts General Hospital

NEALS Network of Excellence for ALS

NEUROLOGICAL CLINICAL RESEARCH INSTITUTE

BARROW Neurological Institute

Berry Consultants Statistical Innovation

MELIORA

ucb

biohaven pharmaceuticals

CLene NANOMEDICINE

prilenia

SEELOS THERAPEUTICS

Calico

DENALI THERAPEUTICS

TACKLE ALS "DON'T BE SORRY LETS BEAT THIS"

ALS ASSOCIATION

MDA Muscular Dystrophy Association

SALSA For a Cure

alsFINDINGaCURE

IAM ALS

TAMBOURINE

ALS ONE

RUN2REVIVE MIND · BODY · POTENTIAL

THE ARTHUR M. BLANK FAMILY FOUNDATION

BASEBALL WINTER MEETINGS SAN DIEGO 2015

AMG The AMG Foundation

ALS Research Ecosystem

Drug Development Pipeline



Managing ALS

- Assistive Technology
- Telehealth / Telemedicine
- Phase IV Medication
- Access / Quality of Life
- Patient Surveys
- Family / Caregiver Burden
- Natural History

Infrastructure, Specimens, Data, Tools, Training

Therapy Evaluation Committee

- Investigational products in the Platform Trial are chosen by a committee of expert ALS scientists and clinicians (>50 applications reviewed to date)
- Industry partners from selected companies work with the Healey Center Trial Design Team, the Network of Excellence for ALS (NEALS), Barrow Neurological Institute and Berry Consultants to tailor a new regimen to their experimental drug
- Each investigational product included in the Platform Trial is believed to have an equal chance of success for all forms of ALS based on available scientific evidence

Criteria for selection include:

- Robust pre-clinical data (data from the lab) that provides strong scientific rationale for testing the product in ALS
- Previous human experience (in ALS or other neurological diseases) to support dose, safety, target engagement, relevant biomarkers
- Clinical trial readiness (availability of investigational product and matching placebo)


A- Zilucoplan
B- Verdiperstat
C- CNM-Au8
D- Pridopidine
E- Trehalose
F- ABBV-CLS-7262
G- DNL343
Glutamate
Astrocyte
Glutamate excitotoxicity
Dysfunction of axonal transport systems
T-Regs
Monocyte/Macrophage
NK
Schwann cell defects
Neuroinflammation
Microglia
Release of proinflammatory cytokines
Ca2+-dependent enzymatic pathways
NAD+ catalysis and ATP production
Sigma-1 receptor agonist
Oxidative stress
Integrated stress response (ISR)
Autophagy
Myeloperoxidase
Complement
C9orf72, TARDBP, FUS, and SOD1 mutations
TDP-43 aggregates
Mitochondrial dysfunction
ER stress
Nucleus
Neuromuscular junction defects
Ion channel dysfunction
Protein aggregates
RNA metabolism
Nucleocytoplasmic trafficking
Muscle
Muscle dysfunction

Individual Learnings Paint Bigger Picture

Moving forward to Phase 3

Regimen A

Regimen B

Regimen C

Regimen D

Regimen E

Regimen F

Regimen G



Broadening the Impact of Placebo Data from Regimens A-E

Regimen A — **Zilucoplan** by UCB → Placebo

Regimen B — **Verdiperstat** by Biohaven → Placebo

Regimen C — **CNM-Au8** By Clene → Placebo

Regimen D — **Pridopidine** by Prilenia → Placebo

Regimen E — **Trehalose** by Seelos → Placebo

Placebo data from Regimens A to E **retired as of Feb 28, 2025** (N=205)

Biosamples include >30,000 cryovials
plasma, serum, urine, whole blood, isolated DNA (genomic data), and cerebrospinal fluid (CSF)

Anonymized data is deposited in PRO-ACT, making it available to researchers by request

PRO-ACT

The Trial Learns from its Experience and Adapts

Revised the Master Protocol to:

- Increase statistical power
- Streamline operations
- Add even more patient-centered features

Study Duration

9 months RCT followed by ATE

Inclusion Criteria

2 years since symptoms onset

Visit Schedule

Increased remote visits (patient-centered)

Biomarkers

New biomarkers and PBMCs for stem cells

New regimens will enroll under the revised Master Protocol

How Companies can Partner with Us

- Submit a **Therapy Application Form**
- The **Therapy Evaluation Committee** meets monthly or ad hoc as needed for reviews and decision is based on science
- Therapy selection is determined in conjunction with the **Executive Committee** to include financial and operational considerations

Scan for Therapy Application Form



Who to Connect With and How

Cudkowicz.merit@mgh.Harvard.edu

Merit Cudkowicz
Director, Sean M. Healey & AMG Center for ALS
Executive Director, MGB Neuroscience Institute
Julieanne Dorn Professor Neurology, Harvard Medical School

HEALEY ALS Platform Trial PI

spaganoni@mgh.Harvard.edu

Sabrina Paganoni
Robert H. Brown, Jr., PhilD, MD
Endowed Chair in Neurology; Co-Director, Neurological Clinical Research Institute
Associate Professor, Harvard Medical School

HEALEY ALS Platform Trial Co-PI

krdrake@mgh.Harvard.edu

Kristin Drake
Senior Director, Sean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute

We accept applications on a rolling basis

Patient Navigation –
Central resource for people living with ALS

Catherine Small
Patient Navigator

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu

Two webinars each month!

Register for webinars:

https://bit.ly/3r6Nd2L

Upcoming Webinars (Thurs, 5:00- 5:30pm Eastern Time)

January 8 – Expanded Access Discussion

January 22 – Research Access Discussion

February 12 – RAPA-501 EAP Update with Rapa Therapeutics